AtriCure Q3 Loss Narrows to $0.01; Revenue Tops $134M, 92% Growth Forecast
AtriCure reported a third-quarter 2025 adjusted loss per share of $0.01, narrowing 90.9% versus estimates, with revenue of $134.3 million topping forecasts by 2.1%. The company projects 2026 earnings growth of 91.7%, significantly outpacing the industry’s 17.7% rate.
1. Q3 2025 Financial Results
AtriCure delivered an adjusted loss per share of $0.01 in the third quarter of 2025, a 90.9% improvement against consensus estimates. Revenue reached $134.3 million, exceeding forecasts by 2.1% as procedural volumes in atrial fibrillation treatment remained robust.
2. 2026 Growth Outlook
The company forecasted earnings growth of 91.7% for 2026, far above the medical devices industry’s projected 17.7% increase. Management cited expanding adoption of its ablation and monitoring technologies as key drivers of the accelerated growth trajectory.
3. Historical Earnings Surprises
Over the past four quarters, AtriCure has beaten earnings estimates with an average surprise of 67.1%. This consistent outperformance highlights the company’s ability to control costs and drive revenue through its surgical and energy-based cardiac treatment portfolio.